Press Releases
Press Releases
Cytheris announces interim results from ECLIPSE II Hepatitis C multicenter study of IL-7 in chronically infected genotype one and four nonresponders to standard of...
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE II Phase I/IIa study indicate that treatment with four weeks...
Press Releases
FDA Approves ERBITUX for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
Eli Lilly and Company and Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved ERBITUX® (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous...
Press Releases
Trophos initiates phase II proof of concept study for novel cardioprotective compound, TRO40303, in acute myocardial infarction
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today that the first patient has been treated in a phase II proof-of-concept study...
Press Releases
Hybrigenics’ specific inhibitor of Ubiquitin-Specific Protease 7 (USP7) is cytotoxic for chronic lymphocytic leukaemia (CLL) cells in vitro
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the presentation by Professor Tatjana Stankovic, from the University of Birmingham (UK) School...
Press Releases
Cytheris to present interim data from ECLIPSE II Hepatitis C multicenter study at AASLD annual meeting
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE II Hepatitis C Phase I/IIa multicenter study will be presented...
Press Releases
TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease
TxCell SA, a biotechnology company developing Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs, announces today the presentation of final positive results of the phase I/II study in Crohn’s disease...
Press Releases
Trophos hosts round-table meetings at ECTRIMS to design POC trial to treat progression in multiple sclerosis
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that Trophos organized two round-table meetings to establish the endpoints and design for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read